Vaccine Hesitancy in Patients with Solid Tumors: a Cross-sectional Single-center Survey

NCT06872814 | Completed

• 1 other identifier: VE
• Study Type: observational
• Target: 309
• Locations: 1 country
• Sites: 1

Brief Summary

Cancer patients have a well-known and higher risk of vaccine-preventable disease (VPD) than the general population. VPD can cause serious complications due to compromised immune system, malnutrition and the same oncology treatments and represent a severe financial burden with a delay in treating the underlying cancer The main purpose of this survey is to analyse the perception of cancer patients on the topic vaccines and vaccine-preventable diseases, the acceptability of vaccines and the evaluation of the determining factors associated with the choice of the patient to be vaccinated or not. This information will be used to improve the management of these issues.

Conditions

Cancer Patients; Vaccine-Preventable Diseases

Outcome Measures

Primary Outcomes (1)

• assess the proportion of vaccinated subjects in our cohort of cancer patients undergoing active cancer treatment

  The primary endpoint will be to assess the proportion of vaccinated subjects in the investigators cohort of cancer patients undergoing active cancer treatment (number of patients who received at least one vaccine/ total number of patients)

  3 months

Secondary Outcomes (5)

• assess the proportion of vaccinated subjects with the anti flu vaccine in the investigators cohort of cancer patients undergoing active cancer treatment

  3 months

• assess the proportion of vaccinated subjects with anti SARS-CoV-2 vaccine in the investigators cohort of cancer patients undergoing active cancer treatment

  3 months

• assess the proportion of vaccinated subjects with anti pneumococccal vaccine in the investigators cohort of cancer patients undergoing active cancer treatment

  3 months

• assess the proportion of vaccinated subjects with anti HZ vaccine in the investigators cohort of cancer patients undergoing active cancer treatment

  3 months

• assess which variables (sex, age, degree of education, marital state, commodities, type of tumor, type of oncological treatment) are associated with not willingness to receive vaccines

  3 months

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The population of this cross-sectional survey will include out-patients of the Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo Pavia

You may qualify if:

• \>18 years of age;
• Oncology patient defined as a patient with solid tumors undergoing active systemic treatment or follow-up;
• Written informed consent

You may not qualify if:

• Patients with hematological tumors
• Patients who are unable to understand informed consent document

Sponsors & Collaborators

• Fondazione IRCCS Policlinico San Matteo di Pavia: lead

Study Sites (1)

Fondazione IRCCS Policlinico San Matteo, SC Oncologia

Pavia, Pavia, 27100, Italy

Location

MeSH Terms

Conditions

Vaccine-Preventable Diseases

Condition Hierarchy (Ancestors)

Infections

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: MD

Study Record Dates

• First Submitted: March 7, 2025
• First Posted: March 12, 2025
• Study Start: May 31, 2024
• Primary Completion: August 26, 2024
• Study Completion: August 26, 2024
• Last Updated: March 17, 2025

Record last verified: 2025-02

Locations

IT (1)